Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

Abstract:

:The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effects by multiple action mechanisms. Vaccinia virus has several inherent features that make it particularly suitable for use as an oncolytic agent. In this review, we will discuss the potential of vaccinia virus in the management of pancreatic cancer in light of our increased understanding of cellular and immunological mechanisms involved in the disease process as well as our extending knowledge in the biology of vaccinia virus.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Al Yaghchi C,Zhang Z,Alusi G,Lemoine NR,Wang Y

doi

10.2217/imt.15.90

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

1249-58

issue

12

eissn

1750-743X

issn

1750-7448

journal_volume

7

pub_type

杂志文章,评审
  • Joint injury and osteoarthritis: soluble mediators in the course and treatment of cartilage pathology.

    abstract::Osteoarthritis is a disabling disease of the aging generation, which results in loss of quality of life and increased healthcare costs. Cytokines appear to play an important role in the cartilaginous degeneration characterizing the pathological process. Increasing experience is being gained with cytokine-modulating th...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.14

    authors: Rutgers M,Saris DB,Yang KG,Dhert WJ,Creemers LB

    更新日期:2009-05-01 00:00:00

  • Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.

    abstract::Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.39

    authors: Muccioli M,Longstaff C,Benencia F

    更新日期:2012-05-01 00:00:00

  • Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'.

    abstract::Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0042

    authors: Ascierto PA,Garbe C

    更新日期:2020-02-01 00:00:00

  • Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis.

    abstract::Only a minority of studies addressing the association between immune-related adverse events (IrAE) and outcome considered the immortal time bias, with conflicting results. PubMed, Embase, Web of Science and Scopus were searched through 2 January 2020. Studies reporting the impact of IrAE on outcome in patients treated...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0179

    authors: Dall'Olio FG,Rizzo A,Mollica V,Massucci M,Maggio I,Massari F

    更新日期:2021-02-01 00:00:00

  • Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy.

    abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0188

    authors: Huang J,Rong L,Wang E,Fang Y

    更新日期:2021-01-01 00:00:00

  • γδ T cells as a potential tool in colon cancer immunotherapy.

    abstract::γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.59

    authors: Ramutton T,Buccheri S,Dieli F,Todaro M,Stassi G,Meraviglia S

    更新日期:2014-01-01 00:00:00

  • Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

    abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.47

    authors: Tanaka T

    更新日期:2013-07-01 00:00:00

  • Tolerogenic dendritic cells for Type 1 diabetes.

    abstract::Evaluation of: Pujol-Autonell I, Ampudia RM, Monge P et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol. doi:10.1155/2013/346987 (2013) (Epub ahead of print). Many reports confirm that dendritic cells (DCs) can prevent aut...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.50

    authors: Giannoukakis N

    更新日期:2013-06-01 00:00:00

  • Mechanisms of immunomodulation in human glioblastoma.

    abstract::Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most dramatic primary brain cancer with a very poor prognosis due to inevitable disease recurrence. Less than 10% of GBM patients are still alive 5 years after diagnosis despite a multimodal treatment with surgical resection of the tumor, radiation therap...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.39

    authors: Avril T,Vauleon E,Tanguy-Royer S,Mosser J,Quillien V

    更新日期:2011-04-01 00:00:00

  • Efficacy and tolerability of a house dust mite allergoid in allergic bronchial asthma: a randomized dose-ranging trial.

    abstract:AIM:This multicenter randomized placebo-controlled double-blind clinical trial investigated which maintenance dose shows the optimal benefit-risk ratio for subcutaneous immunotherapy with a Dermatophagoides pteronyssinus allergoid preparation. OBJECTIVE:To evaluate four maintenance doses of the allergoid preparation v...

    journal_title:Immunotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2217/imt-2018-0087

    authors: Jutel M,Rudert M,Kreimendahl F,Kuna P

    更新日期:2018-09-01 00:00:00

  • Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.

    abstract::Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.7

    authors: Smith C,Khanna R

    更新日期:2015-01-01 00:00:00

  • A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.

    abstract::Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0020

    authors: Araújo M,Ligeiro D,Costa L,Marques F,Trindade H,Correia JM,Fonseca C

    更新日期:2017-06-01 00:00:00

  • EBV and nasopharyngeal carcinoma: a target for cellular therapies.

    abstract::Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.68

    authors: Smith C

    更新日期:2013-08-01 00:00:00

  • The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

    abstract::NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.117

    authors: Subleski JJ,Jiang Q,Weiss JM,Wiltrout RH

    更新日期:2011-10-01 00:00:00

  • Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.

    abstract::Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0181

    authors: El-Khazragy N,Ghozy S,Emad P,Mourad M,Razza D,Farouk YK,Mohamed NA,Ahmed MK,Youssef T,Bahnasawy YM,Elmasery S

    更新日期:2020-12-01 00:00:00

  • Passive immune neutralization strategies for prevention and control of influenza A infections.

    abstract::Although vaccination significantly reduces influenza severity, seasonal human influenza epidemics still cause more than 250,000 deaths annually. Vaccine efficacy is limited in high-risk populations such as infants, the elderly and immunosuppressed individuals. In the event of an influenza pandemic (such as the 2009 H1...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.167

    authors: Ye J,Shao H,Perez DR

    更新日期:2012-02-01 00:00:00

  • Checkpoint inhibition in meningiomas.

    abstract::Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evide...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0017

    authors: Bi WL,Wu WW,Santagata S,Reardon DA,Dunn IF

    更新日期:2016-06-01 00:00:00

  • Preventing stem cell transplantation-associated viral infections using T-cell therapy.

    abstract::Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.43

    authors: Tzannou I,Leen AM

    更新日期:2015-01-01 00:00:00

  • Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report.

    abstract::Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with r...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0223

    authors: Mulroy M,Ghafouri S,Sisk A,Ribas A,Goshtaseb R,Cherry G,Shen J

    更新日期:2021-03-01 00:00:00

  • mRNA: delivering an antitumor message?

    abstract::Evaluation of: Fotin-Mleczek M, Duchardt KM, Lorenz C et al.: Messenger RNA-based vaccines with dual activity induce balanced TLR7-dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011). Two decades ago, mRNA was proposed as an active pharmaceutical ingredient for the the...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.11.28

    authors: Van Lint S,Thielemans K,Breckpot K

    更新日期:2011-05-01 00:00:00

  • Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.

    abstract::Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/1750743X.1.2.281

    authors: Kresowik TP,Griffith TS

    更新日期:2009-03-01 00:00:00

  • Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.

    abstract::Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.11

    authors: Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

    更新日期:2014-01-01 00:00:00

  • MAGE-A3: an immunogenic target used in clinical practice.

    abstract::Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.29

    authors: Esfandiary A,Ghafouri-Fard S

    更新日期:2015-01-01 00:00:00

  • Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity.

    abstract::There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.75

    authors: Tamura Y,Torigoe T,Kukita K,Saito K,Okuya K,Kutomi G,Hirata K,Sato N

    更新日期:2012-08-01 00:00:00

  • Antibody-based immunotherapy of solid cancers: progress and possibilities.

    abstract::Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.57

    authors: Nicodemus CF

    更新日期:2015-01-01 00:00:00

  • PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.

    abstract:AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible...

    journal_title:Immunotherapy

    pub_type: 杂志文章,meta分析

    doi:10.2217/imt-2016-0025

    authors: Abdel-Rahman O

    更新日期:2016-09-01 00:00:00

  • Immunotherapy targeting colon cancer stem cells.

    abstract::In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinic...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.87

    authors: Iovino F,Meraviglia S,Spina M,Orlando V,Saladino V,Dieli F,Stassi G,Todaro M

    更新日期:2011-01-01 00:00:00

  • Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.

    abstract::Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various infl...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2019-0191

    authors: Boyle JV,Lam K,Han JK

    更新日期:2020-02-01 00:00:00

  • The safety profile of Polyoxidonium in daily practice: results from postauthorization safety study in Slovakia.

    abstract:AIM:This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS:A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety...

    journal_title:Immunotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.2217/imt-2017-0116

    authors: Pružinec P,Chirun N,Sveikata A

    更新日期:2018-02-01 00:00:00

  • Designing two-in-one antibodies.

    abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.09.39

    authors: Valladares IG,Espinoza LR

    更新日期:2009-09-01 00:00:00